Background/Aims: The incidence of colorectal cancer has been increasing every year in Korea. Irinotecan-or oxaliplatin-based regimens including biologic agents are known to be effective in patients with advanced colorectal cancer. But in practice, FOLFOX (combination of oxaliplatin, 5-fluorouracil, and leucovorin) or FOLFIRI (combination of irinotecan, 5-fluorouracil, and leucovorin) regimens without biologic agents are more commonly used in Korea due to of the high costs of biologic agents. The aim of this study was to evaluate the efficacy and toxicity of FOLFIRI following FOLFOX4 in patients with advanced colorectal cancer. Methods: A total of 54 patients with advanced colorectal cancer who were treated between May 2005 and May 2013 with FOLFOX4 as first-line chemotherapy and with FOLFIRI as second-line chemotherapy at Kosin University Gospel Hospital (Busan, Korea) were reviewed retrospectively. Results: A total of 54 patients received second-line FOLFIRI chemotherapy. Five patients (9.3%) had a partial response, 29 patients (53.7%) had a stable disease. The median overall survival was 8.90 months and the median time to progression was 4.33 months. Toxicities were tolerable. Conclusions: In a Korean population, FOLFIRI as second-line chemotherapy is effective and well tolerated in patients with advanced colorectal cancer after failure of FOLFOX4. Although the efficacy of FOLFIRI in this study was lower than that of second-line FOLFIRI with biologic agents, these results can help in the formulation of a treatment strategy for financially troubled patients. (Korean J Gastroenterol 2014;63:18-24) 
INTRODUCTION
Colorectal cancer is ranked as the third leading cause of cancer-related death in the world. In Korea, according to data from the Korean National Cancer Center, the incidence of colorectal cancer has been increasing every year. The age-standardized incidence rate of colorectal cancer in men was 27.0 per 100,000 in 1999 and 49.8 per 100,000 in 2010 and in women was 17.1 per 100,000 in 1999 and 26.4 per 100,000 in 2010. The age-standardized mortality rate of colorectal cancer was 10.8%, and its 5-year overall survival rate was Although surgery is potentially curative, about one-third of newly diagnosed patients have distant metastasis and are not candidates for curative surgery. 2 Chemotherapy is an ef- rates and times to progression. 8 Tournigand et al. 4 reported that the two sequences (FOLFOX→FOLFIRI vs. FOLFIRI→ FOLFOX) were similar in efficacy and showed no significant difference of median overall survival or time to progression.
In patients with advanced colorectal cancer, these regimens can be combined with biologic agents that have been shown to improve the overall survival compared to treatment without biologic agents. 9 In Korea, however, due to the high costs of biologic agents, the majority of patients cannot easily opt to use them. 
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Statistical analysis
The overall survival was measured from the first day of was used for statistical analysis.
RESULTS

Patient characteristics
Among the 54 patients examined, the median age was 65 Values are presented as n (%). FOLFIRI, combination of irinotecan, 5-fluorouracil, and leucovorin; FOLFOX, combination of oxaliplatin, 5-fluorouracil, and leucovorin. 
Efficacy of treatment
The median number of first-line FOLFOX4 chemotherapy cycles per patient was 11 (range, , and the median number of second-line FOLFIRI chemotherapy cycles per patient was eight (range, 2-46). No patients had complete response (0%), five patients had partial response (9.3%), and 29 patients had stable disease (53.7%). The response rate was 9.3%, and the disease control rate was 63.0%. Thirteen patients had progressive disease (24.1%), and tumor responses could not be assessed in seven patients (13.0%).
These results are summarized in Table 2 . Twenty-three patients experienced a change of chemotherapy regimens as a result of disease progression (42.6%).
The median overall survival for the FOLFIRI regimen was 8.90 months (95% confidence interval, 5.76-12.04 months) (Fig. 1) , and the median time to progression for the FOLFIRI regimen was 4.33 months (95% confidence interval, 2.51-6.16 months) (Fig. 2) .
Toxicity
Patients received a total of 426 cycles of FOLFIRI chemotherapy. The most common toxicity was neutropenia, which occurred in 43 patients (79.6%). Grade 3 or 4 anemia occurred in nine patients (16.7%), grade 3 or 4 neutropenia occurred in 34 patients (62.9%), and grade 3 or 4 thrombocytopenia occurred in six patients (11.1%). Five patients had neutropenic fever that improved after treatment with G-CSF (granulocyte-colony stimulating factor) and antibiotics.
Twelve patients required dose reduction (22.2%) due to neutropenia. No deaths occurred due to toxicity. Non-hematologic toxicities consisted primarily of nausea and vomiting
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DISCUSSION
Irinotecan, a semisynthetic analogue of the natural alkaloid camptothecin, binds to the topoisomerase I-DNA complex and is involved in the unwinding of DNA during replication. 10 It was clinically introduced in the late 1980s
and has demonstrated antitumor activity against advanced colorectal cancer when used alone as first-line or second-line treatment. 11, 12 The main toxicities observed with irinotecan are delayed-onset diarrhea, nausea, vomiting, neutropenia, fatigue, alopecia, and acute cholinergic-like syndrome. 13 The activity of irinotecan against untreated and fluorouracil-resistant colorectal cancer is the basis of the FOLFIRI regimen. This study aimed to assess the efficacy and toxicity of FOLFIRI without biologic agents as second-line chemotherapy after a failure of FOLFOX4 in patients with advanced colorectal cancer in a Korean population. In this study, RR was 9.3%. The median overall survival and median time to progression were 8.9 months and 4.33 months, respectively.
Several phase II studies shown in Table 4 have reported the efficacy of the FOLFIRI regimen as second-line chemotherapy after failure of the FOLFOX regimen, 7 with results similar to ours. In those studies, the RR range was 4-23%, the median overall survival range was 7.8-10.5 months, and the median time to progression range was 2.3-4.8 months.
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The treatment was well-tolerated and neutropenia was the most frequently observed grade 3 or 4 toxicity (27.2%).
Previous studies showed that grade 3 or 4 neutropenia occurred in about 12.9-37.0% of patients with advanced colorectal cancer treated with second-line FOLFIRI. In this study, there was no grade 3 or 4 diarrhea and 11 patients (20.4%) had grade 1 or 2 diarrhea. The rate of grade 3 or 4 diarrhea was reported to be 29% in French patients, 4 2.4% in Chinese patients, 24 and 0% in Korean patients treated with 180 mg/m 2 irinotecan. 7, 25, 26 These differences in incidence of diarrhea could be explained by ethnic allelic differences in uridine diphosphate glucuronosyltransferase 1 (UGT1A1).
Irinotecan is metabolized to SN-38, which causes diarrhea and is inactivated by UGT1A1. The UGT1A1 (TA) 6/6 genotype is significantly more common in Asians than in Caucasians (76% vs. 46%). 27 The comparison between data from this study and that from other studies using second-line FOLFIRI chemotherapy is summarized in Table 4 .
In conclusion, the results of this study emphasize the efficacy of FOLFIRI as second-line chemotherapy after failure of FOLFOX4 in advanced colorectal cancer in a Korean population. Although the efficacy of FOLFIRI in this study was lower than that of second-line FOLFIRI with biologic agents, these results can help in the formulation of a treatment strategy for financially troubled patients.
